News

 

Contact Media Relations

Office telephone: +39 0331 581380
mediarelations@nmsgroup.it

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

Nerviano, 1 February 2024     The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 000 international patent families (IPFs) have been registered by Italian companies and research facilities. Among them, Nerviano Medical Sciences stands out as the top applicant during the 2002-2021 period.

(Click the title for the complete article)

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

NERVIANO Italy and PARIS France, January 8, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project.

(Click the title for the complete article)

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

NERVIANO and MILAN, Italy, December 14, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).

(Click the title for the complete article)

Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS Srl, Bringing Extensive Global Biopharmaceutical Experience

Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS Srl, Bringing Extensive Global Biopharmaceutical Experience

NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Serena Alvino as its Chief Legal, Biotech & Transaction, effective immediately.

(Click the title for the complete article)

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

Nerpharma is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.

Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company’s strategic direction and ensuring operational efficiency.

(Click the title for the complete article)

NMS Srl proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society

NMS Srl proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society

We are pleased to announce that Dr. Gianluca Papeo and Dr. Maurizio Pulici from NMS Srl are invited to be part of the permanent round table of the Pharmaceutical Division of the Italian Chemical Society (SCI) which gathers representative of the Italian Pharmaceutical industry and the Academic world to liaise their relationships under the patronage of the SCI.

(Click the title for the complete article)

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Tiziano Lazzaretti as its new Chief Financial Officer (CFO). Tiziano brings a wealth of leadership experience in corporate strategies, finance, and governance, acquired across diverse industries, including chemicals, pharmaceuticals and biotechnology sectors.

(Click the title for the complete article)

 Our Archive

MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018
MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO